Domperidone: Gut Motility, Lactation, and Cardiac Safety

Domperidone is a prescription anti-nausea and gut-motility drug used widely outside the United States but never approved by the FDA for sale within it. It works by blocking dopamine receptors in the gut wall and in the brain’s vomiting center, speeding up stomach emptying and quieting nausea without most of the neurological side effects of its better-known cousin, metoclopramide. That combination of effectiveness and a relatively clean central-nervous-system profile has made it a go-to treatment for gastroparesis in many countries, though a real cardiac safety concern keeps regulators cautious.

How Domperidone Works

Dopamine naturally slows down motility in the upper digestive tract. Domperidone blocks the D2 dopamine receptors on the muscle cells of the stomach and the upper small intestine, releasing the brakes on motility and helping food move through more quickly. It also blocks dopamine receptors in the chemoreceptor trigger zone, a small area of the brainstem that sits outside the blood-brain barrier and acts as a nausea surveillance station. By silencing dopamine signaling there, domperidone suppresses the urge to vomit.¹

The key distinction between domperidone and many other dopamine-blocking drugs is how poorly it crosses the blood-brain barrier. PET imaging studies in humans have confirmed that domperidone’s brain exposure is roughly 2.4-fold lower than that of metoclopramide, consistent with much lower penetration across the barrier.² That limited brain penetration is what spares most patients from the drowsiness, restlessness, and involuntary-movement problems that plague drugs like metoclopramide. There is a practical trade-off, though: when domperidone is taken by mouth, it undergoes heavy first-pass metabolism in the liver, so a large fraction of each dose is broken down before it ever reaches the bloodstream.³

Gastroparesis and Other Gut Uses

The condition domperidone is most associated with is gastroparesis, a disorder in which the stomach empties abnormally slowly despite no physical blockage. Symptoms range from persistent nausea and bloating to vomiting and poor nutrition. In a study of patients with gastroparesis, chronic domperidone therapy cut the amount of solid food still sitting in the stomach at two hours from about 87% retention down to about 57%, bringing emptying into the normal range. Patients also reported fewer symptoms, better quality of life, and fewer hospitalizations.⁴ In children with diabetic gastroparesis specifically, domperidone reduced gastric emptying time more effectively than cisapride, a once-popular motility drug that was eventually pulled from many markets over its own cardiac risks.⁵

Domperidone also plays a notable role in managing nausea caused by Parkinson’s disease medications. Dopamine-boosting drugs like levodopa and apomorphine often cause severe nausea, and since most standard anti-nausea drugs work by blocking dopamine, they risk undoing the very therapy the patient needs. Domperidone, which stays mostly outside the brain, can ease nausea without blunting the neurological benefits. A French study of Parkinson’s patients found that domperidone was prescribed to about 7% of those on dopaminergic therapy, predominantly for nausea during apomorphine infusions or other dopamine-replacement treatments.⁶ That same study, however, flagged widespread “misuse” by European regulatory standards: 95% of prescriptions violated at least one guideline, most commonly by exceeding the recommended seven-day treatment limit or by prescribing to patients over 60 who face higher cardiac risk. The gap between how regulators think the drug should be used and how clinicians actually use it is a recurring theme.

The Cardiac Safety Question

The main reason domperidone remains unavailable in the United States and carries strict restrictions in Europe is its effect on the heart’s electrical cycle. Like several other drugs that block dopamine receptors, domperidone also blocks a potassium channel in heart cells called hERG. This channel helps reset the heart’s electrical charge between beats, and when it is inhibited, the interval between one heartbeat’s electrical wave and the next (the QT interval) can stretch. A prolonged QT interval raises the risk of a dangerous heart rhythm called torsades de pointes, which can degenerate into cardiac arrest.

Lab studies have shown that domperidone blocks hERG channels at concentrations well within the range the drug reaches in the bloodstream, and it does so far more potently than metoclopramide.⁷ Animal heart models confirmed that domperidone lengthened cardiac repolarization at clinically relevant concentrations, prompting researchers to caution that it should not be treated as a risk-free alternative to cisapride.⁸ Epidemiological reviews have similarly linked domperidone to increased rates of serious ventricular arrhythmia and sudden cardiac death, particularly in older adults and those taking higher doses.⁹

The clinical picture is more nuanced than those lab and epidemiological findings might suggest, though. A large single-center study of gastroparesis patients taking conventional doses of 30 to 80 mg per day found that only about 6% showed QT prolongation on electrocardiogram, and none reached the threshold generally considered clinically dangerous. The authors concluded that domperidone can be safely prescribed at those doses for gastroparesis treatment.¹⁰ For patients with systemic sclerosis receiving long-term, low-dose domperidone for gut dysmotility, no marked safety concerns emerged either.¹¹ The consensus view is that the cardiac risk is real but concentrated in specific groups: older patients, those with pre-existing heart conditions, people taking higher doses, and especially those also taking drugs that interfere with domperidone’s metabolism.

Drug Interactions That Amplify the Risk

Domperidone is broken down primarily by the liver enzyme CYP3A4. When another drug inhibits that enzyme, domperidone levels in the blood can climb substantially. The antifungal ketoconazole, a potent CYP3A4 inhibitor, tripled steady-state domperidone concentrations in a controlled crossover study. In men, the combination produced QT prolongation averaging about 16 ms above placebo, compared with about 4 ms for domperidone alone.¹² Interestingly, women in the same study did not show a statistically significant increase in QT interval from either drug alone or in combination, though their QT intervals still correlated with blood drug concentrations.

A nationwide case-crossover study found that people co-exposed to domperidone and CYP3A4 inhibitors had roughly double the odds of ventricular arrhythmia compared with those on domperidone alone.¹³ This matters practically because common CYP3A4 inhibitors include many antifungals, certain antibiotics (clarithromycin, erythromycin), some HIV medications, and even grapefruit juice in large amounts. Anyone taking domperidone should be aware that these combinations can quietly push drug levels into a riskier range.

How Domperidone Compares with Metoclopramide

Because domperidone is not available in the United States, American patients with gastroparesis usually get metoclopramide instead. Both drugs block D2 receptors and speed gastric emptying, and head-to-head trials generally show similar efficacy. The trade-off is in side effects, and it is stark. In a double-blind multicenter comparison, nearly half of patients on metoclopramide reported drowsiness, compared with about 29% on domperidone. A third of the metoclopramide group reported reduced mental sharpness, versus a fifth on domperidone. Those differences were statistically significant.¹⁴

The most feared metoclopramide side effect is tardive dyskinesia, an involuntary movement disorder that can be irreversible. Because metoclopramide freely enters the brain, prolonged use carries a meaningful risk of extrapyramidal symptoms. A systematic review and meta-analysis found that restlessness, an extrapyramidal side effect, occurred in about 15% of metoclopramide-treated patients, a seven-fold increase over placebo.¹⁵ Domperidone’s limited brain penetration largely sidesteps this problem, which is why many gastroenterologists outside the US consider it the preferable first-line agent. The catch is that domperidone carries more cardiac risk. Each drug has a different worst-case scenario, and for a given patient the choice depends on whether neurological or cardiac risk matters more.

Boosting Milk Supply in Breastfeeding Mothers

One of domperidone’s most talked-about uses has nothing to do with nausea or gastroparesis. Because blocking dopamine receptors at the pituitary gland causes prolactin levels to rise, domperidone reliably increases breast milk production. This is an off-label use everywhere, meaning no regulatory agency has formally approved domperidone for lactation support, but it has become common practice in Canada, Australia, and parts of Europe, particularly for mothers of premature infants who are struggling to express enough milk.

A systematic review pooling five trials of mothers of preterm infants found that domperidone produced a moderate increase in daily milk volume of about 88 mL per day compared with placebo.¹⁶ An earlier randomized trial showed a 44.5% increase in milk production over baseline in the domperidone group versus 16.6% with placebo after just seven days.¹⁷ Another trial reported that milk volume roughly doubled from baseline after two weeks of treatment, accompanied by a significant jump in prolactin levels.¹⁸

There is an important caveat: the benefit is clearest in mothers of preterm infants. A Bayesian network meta-analysis comparing domperidone with metoclopramide and placebo found that preterm mothers on domperidone saw significantly greater milk increases, but term mothers did not show a statistically significant benefit over either comparator.¹⁹ This may reflect that term mothers generally have stronger milk supply to begin with, leaving less room for a medication to help, but whatever the reason, it complicates the routine prescribing of domperidone for any mother with low supply.

Parents often worry about how much drug ends up in the milk itself. A dose-effect study measuring domperidone concentrations in breast milk found extremely low transfer. At the standard 30 mg daily dose, the relative infant dose was about 0.012% of the maternal dose, a level researchers considered insignificant.²⁰

Withdrawal Symptoms When Stopping

A lesser-known aspect of domperidone that catches some patients off guard is the possibility of withdrawal symptoms, particularly after extended use for lactation. Case reports have documented women experiencing anxiety, agitation, insomnia, and other psychiatric symptoms lasting weeks to months during tapering or after abrupt cessation.²¹ In one published case, a woman’s withdrawal symptoms resolved after restarting the drug and only cleared fully with a much slower taper.²²

The mechanism likely involves the body adapting to chronic dopamine-receptor blockade. When the drug is suddenly removed, the abrupt shift in dopamine signaling can trigger a rebound. This is the same general principle behind withdrawal from many drugs that alter neurotransmitter systems, but it tends to surprise people because domperidone is thought of as a gut drug with minimal brain effects. The pituitary gland, however, sits outside the blood-brain barrier, and long-term prolactin elevation and dopamine-receptor changes there may be enough to cause problems on discontinuation. The practical takeaway is that anyone who has been on domperidone for weeks or months should work with their prescriber on a gradual taper rather than stopping cold.

Domperidone in Children

Domperidone has been used in pediatric settings, especially for gastroesophageal reflux in infants and toddlers, but the evidence supporting that use is thin. A systematic review of randomized controlled trials in children aged one month to 11 years concluded that there was no robust evidence of efficacy for treating reflux with domperidone in young children, and given that reflux is usually self-limiting in this age group, the authors questioned the widespread use of unlicensed medications for it.²³ A single-center trial echoed this, finding that four weeks of domperidone reduced the total number of reflux episodes in the postprandial period but did not translate to meaningful symptom improvement. Some patients did improve after eight weeks, suggesting a longer course might help a subset, but the overall signal was weak.²⁴

On the cardiac safety side in children, a study of patients under two years old found that short-term domperidone treatment did not significantly lengthen the QT interval. Two children did develop QT values above 450 milliseconds, but both were also taking lansoprazole, a proton-pump inhibitor that can independently affect cardiac conduction.²⁵ So the cardiac worry appears smaller in children than in elderly adults, but the efficacy case is also weaker, leaving pediatricians in a gray zone where off-label prescribing persists despite limited justification.

Why It Is Not Available in the United States

The FDA has never approved domperidone for marketing in the United States. The agency issued import alerts and warnings against its use as early as 2004, citing the cardiac risks. American patients with severe gastroparesis can sometimes obtain it through the FDA’s Investigational New Drug (IND) compassionate-use pathway, which requires a physician to apply on the patient’s behalf. In practice, this is cumbersome enough that many patients either go without or turn to informal importation from Canadian or overseas pharmacies, a legal gray area that the FDA has intermittently cracked down on.

In Europe, the European Medicines Agency conducted a safety review in 2014 and recommended restricting domperidone to short courses (up to one week) at a maximum dose of 30 mg per day for adults. Many European clinicians, as the French Parkinson’s study showed, routinely exceed those limits when treating chronic conditions like gastroparesis or long-term nausea from Parkinson’s medications. Canada and Australia have maintained domperidone on the market with less stringent restrictions, and it remains available over the counter in some countries in Asia and Africa, sometimes without meaningful regulatory oversight.

An Uncommon Use in Endocrine Testing

Beyond its therapeutic applications, domperidone has found a niche in diagnostic endocrinology. Because it blocks dopamine at the pituitary without crossing the blood-brain barrier, it can be used as a provocative test to stimulate prolactin release and evaluate pituitary function. Researchers have used a single dose of domperidone to differentiate between causes of elevated prolactin. In one study comparing patients with empty sella syndrome (a condition where the pituitary gland is flattened by cerebrospinal fluid) against patients with prolactin-secreting tumors, the prolactin response to domperidone helped distinguish the two groups.²⁶ That said, these provocative tests have never achieved clear enough diagnostic separation to become routine. Most endocrinologists today rely on imaging and baseline lab values rather than stimulation tests to sort out elevated prolactin levels, so the domperidone stimulation test remains a curiosity more than a staple.